DK1961821T3 - Erythropoietin-fusionsprotein - Google Patents

Erythropoietin-fusionsprotein

Info

Publication number
DK1961821T3
DK1961821T3 DK07003659T DK07003659T DK1961821T3 DK 1961821 T3 DK1961821 T3 DK 1961821T3 DK 07003659 T DK07003659 T DK 07003659T DK 07003659 T DK07003659 T DK 07003659T DK 1961821 T3 DK1961821 T3 DK 1961821T3
Authority
DK
Denmark
Prior art keywords
fusion proteins
carbamoylated
epo
fusion protein
relates
Prior art date
Application number
DK07003659T
Other languages
English (en)
Inventor
Robert Weik
Thomas Hemetsberger
Heinz Redl
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Application granted granted Critical
Publication of DK1961821T3 publication Critical patent/DK1961821T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heat Treatment Of Articles (AREA)
DK07003659T 2007-02-22 2007-02-22 Erythropoietin-fusionsprotein DK1961821T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20070003659 EP1961821B1 (en) 2007-02-22 2007-02-22 Erythropoietin fusion protein

Publications (1)

Publication Number Publication Date
DK1961821T3 true DK1961821T3 (da) 2009-10-12

Family

ID=37972378

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07003659T DK1961821T3 (da) 2007-02-22 2007-02-22 Erythropoietin-fusionsprotein

Country Status (15)

Country Link
US (1) US9085640B2 (da)
EP (1) EP1961821B1 (da)
JP (1) JP5588684B2 (da)
KR (1) KR101539120B1 (da)
CN (1) CN101688210B (da)
AT (1) ATE433492T1 (da)
AU (1) AU2008217202B2 (da)
BR (1) BRPI0807786A2 (da)
CA (1) CA2678986C (da)
DE (1) DE602007001273D1 (da)
DK (1) DK1961821T3 (da)
EA (1) EA017377B1 (da)
ES (1) ES2327170T3 (da)
PL (1) PL1961821T3 (da)
WO (1) WO2008101680A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2239569A1 (en) * 2009-04-09 2010-10-13 Lophius Biosciences GmbH Method for polypeptide transfer into cells
TWI626946B (zh) 2015-01-09 2018-06-21 格納西尼有限公司 使用持續釋放epo之製劑治療貧血之方法
KR101847169B1 (ko) * 2015-10-07 2018-04-09 주식회사 녹십자 지속형 에리트로포이에틴 함유 조성물
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002709A1 (en) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
CN1234731C (zh) * 2003-01-30 2006-01-04 旭华(上海)生物研发中心有限公司 具有高度生物活性的人促红细胞生成素的Fc融合蛋白
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
JP2008505184A (ja) * 2004-07-02 2008-02-21 ザ ケネス エス.ウォーレン インスティテュート,インコーポレーテッド 完全にカルバミル化されたエリトロポイエチンを生成する方法
WO2006014466A2 (en) * 2004-07-02 2006-02-09 The Kenneth S. Warren Institute, Inc. Novel carbamylated epo and method for its production
EP1781697B1 (en) * 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
US20070243132A1 (en) 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
WO2008065372A2 (en) * 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment

Also Published As

Publication number Publication date
CN101688210B (zh) 2013-08-14
US20100203050A1 (en) 2010-08-12
CA2678986C (en) 2016-04-19
AU2008217202B2 (en) 2014-06-12
EA017377B1 (ru) 2012-12-28
ES2327170T3 (es) 2009-10-26
PL1961821T3 (pl) 2010-01-29
AU2008217202A1 (en) 2008-08-28
KR101539120B1 (ko) 2015-07-29
KR20090122430A (ko) 2009-11-30
EP1961821A1 (en) 2008-08-27
JP5588684B2 (ja) 2014-09-10
CA2678986A1 (en) 2008-08-28
BRPI0807786A2 (pt) 2014-06-24
JP2010520859A (ja) 2010-06-17
WO2008101680A1 (en) 2008-08-28
EA200970782A1 (ru) 2010-08-30
US9085640B2 (en) 2015-07-21
CN101688210A (zh) 2010-03-31
ATE433492T1 (de) 2009-06-15
DE602007001273D1 (de) 2009-07-23
EP1961821B1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
JP7307836B2 (ja) 組換えfviii変異型をコードする血友病a遺伝子治療用高発現ウイルスベクター
JP6527918B2 (ja) 第viii因子組成物、ならびに組成物の作製方法および用途
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
IN2012DN02981A (da)
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
ES2678144T3 (es) Composiciones relacionadas con SAH y métodos de uso
MX2009002816A (es) Proteinas de fusion de albumina.
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
TNSN08064A1 (en) Albumin fusion proteins
ATE517118T1 (de) Bis-met-histone
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
BRPI0507026A (pt) proteìnas de fusão de albumina
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA201171259A1 (ru) Антительные гибридные белки с модифицированными сайтами связывания fcrn
EA200970782A1 (ru) Слитый белок эритропоэтина
EA201100071A1 (ru) Новые композиции и способы
US20190127438A1 (en) Alpha chain of the high-affinity ige receptor (fceria)
JP2017521070A (ja) 改変フォンウィルブランド因子
WO2022178090A3 (en) Dnase fusion polypeptides and related compositions and methods
Kim et al. Construction of chimeric human epidermal growth factor containing short collagen-binding domain moieties for use as a wound tissue healing agent
JP2013517782A5 (da)
JP2009536821A5 (da)